NYSE:MYOVMyovant Sciences Stock Price, Forecast & News

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYOV shares have increased by 107.0% and is now trading at $18.01. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myovant Sciences.

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Myovant Sciences.

Myovant Sciences Ltd (NYSE:MYOV) posted its quarterly earnings results on Monday, May, 18th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. View Myovant Sciences' earnings history.

7 brokerages have issued 12 month price targets for Myovant Sciences' stock. Their forecasts range from $20.00 to $55.00. On average, they expect Myovant Sciences' share price to reach $30.67 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View analysts' price targets for Myovant Sciences.

Press coverage about MYOV stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myovant Sciences earned a news impact score of 1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Myovant Sciences.

Myovant Sciences saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 3,020,000 shares, a drop of 5.3% from the May 31st total of 3,190,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the short-interest ratio is presently 2.5 days. Approximately 9.7% of the shares of the stock are short sold. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), Global Blood Therapeutics (GBT) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Energy Transfer LP Unit (ET), Amarin (AMRN), NVIDIA (NVDA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Carnival (CCL), Coty (COTY), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD) and Micron Technology (MU).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $18.01.

Myovant Sciences has a market capitalization of $1.62 billion. The company earns $-288,990,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.

The official website for Myovant Sciences is myovant.com.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3351 or via email at [email protected]